Alterity Therapeutics Limited

NasdaqCM:ATHE Stock Report

Market Cap: US$33.1m

Alterity Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Stamler

Chief executive officer

AU$1.4m

Total compensation

CEO salary percentage50.4%
CEO tenure4yrs
CEO ownership0.2%
Management average tenure13yrs
Board average tenure18.7yrs

Recent management updates

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

CEO Compensation Analysis

How has David Stamler's remuneration changed compared to Alterity Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$1mAU$717k

-AU$19m

Mar 31 2024n/an/a

-AU$16m

Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$13m

Jun 30 2023AU$2mAU$731k

-AU$14m

Mar 31 2023n/an/a

-AU$14m

Dec 31 2022n/an/a

-AU$14m

Sep 30 2022n/an/a

-AU$14m

Jun 30 2022AU$2mAU$658k

-AU$13m

Mar 31 2022n/an/a

-AU$13m

Dec 31 2021n/an/a

-AU$13m

Sep 30 2021n/an/a

-AU$14m

Jun 30 2021AU$979kAU$606k

-AU$15m

Mar 31 2021n/an/a

-AU$16m

Dec 31 2020n/an/a

-AU$16m

Sep 30 2020n/an/a

-AU$15m

Jun 30 2020AU$625kAU$625k

-AU$13m

Mar 31 2020n/an/a

-AU$13m

Dec 31 2019n/an/a

-AU$13m

Sep 30 2019n/an/a

-AU$12m

Jun 30 2019AU$548kAU$548k

-AU$12m

Mar 31 2019n/an/a

-AU$11m

Dec 31 2018n/an/a

-AU$10m

Sep 30 2018n/an/a

-AU$9m

Jun 30 2018AU$630kAU$504k

-AU$8m

Compensation vs Market: David's total compensation ($USD884.15K) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Stamler (63 yo)

4yrs

Tenure

AU$1,422,068

Compensation

Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...

Leadership Team

NamePositionTenureCompensationOwnership
Geoffrey Kempler
Co-Founder & Non-Executive Chairman27.2yrsAU$280.00k0.28%
$ 92.0k
David Stamler
Chief Executive Officer4yrsAU$1.42m0.20%
$ 66.5k
Abby Macnish Niven
CFO & Company Secretaryless than a yearno datano data
Rudolph Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board13yrsno datano data
Steven Targum
Chief Medical Advisor17.8yrsno datano data
Robert Cherny
Head of Research17.8yrsno datano data

13.0yrs

Average Tenure

66yo

Average Age

Experienced Management: ATHE's management team is seasoned and experienced (13 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Geoffrey Kempler
Co-Founder & Non-Executive Chairman27.2yrsAU$280.00k0.28%
$ 92.0k
Rudolph Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board17.8yrsno datano data
Brian Meltzer
Non-Executive Independent Director25.1yrsAU$70.00k0.14%
$ 46.4k
Colin Masters
Member of Research & Development Advisory Board17.8yrsAU$241.36kno data
Peter Marks
Non-Executive Independent Director19.5yrsAU$70.00k0.14%
$ 44.7k
Lawrence Gozlan
Non-Executive Director13.4yrsAU$70.00kno data
Ira Shoulson
Chairman of Research & Development Advisory Boardno dataAU$78.76kno data

18.7yrs

Average Tenure

69yo

Average Age

Experienced Board: ATHE's board of directors are seasoned and experienced ( 18.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 04:45
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alterity Therapeutics Limited is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George ZavoicoB. Riley Securities, Inc.
Vernon BernardinoFBR Capital Markets & Co.
George ZavoicoH.C. Wainwright & Co.